The importance of up-regulation of NK-1R in squamous carcinomas also concerns the possibility of performing a targeted tumor therapy on NK-1R, and there are currently at least 3 phase 4 clinical trials on this topic (NCT00588835; NCT02532634; NCT04134208. Here, TACR1 is linked to squamous cell carcinoma.